A San Francisco startup supported by OpenAI launched AI models capable of designing antibodies with significantly higher lab success rates compared to existing protein models. Concurrently, Pfizer expanded their AI-driven drug discovery collaboration with XtalPi to enhance molecular modeling capabilities. These developments position AI as a transformative tool in biologic innovation and small-molecule drug development pipelines.